StimCell Energetics Inc. (OTCQB: STME), a biotech company focused on enhancing cellular energy for wellness and longevity, has announced the engagement of Stonegate Capital Partners, Inc. to provide research coverage and institutional investor outreach services. This partnership, formalized through an Advisory Services Agreement effective March 12, 2026, aims to elevate the company's visibility and build institutional ownership. As part of the agreement, StimCell will issue 250,000 shares of its common stock to Stonegate as compensation for the initial twelve-month term. Stonegate, with over 50 years of experience and a robust network of investment firms, will deliver comprehensive services including quarterly updated research and ongoing investor relations consultation. The agreement allows for cancellation by either party with a 30-day written notice after the initial term. This strategic move is expected to enhance StimCell's outreach to a broader investor audience, supporting its long-term growth objectives. The shares issued will be subject to a six-month hold period and are being issued under exemptions from the registration requirements of the U.S. Securities Act of 1933. This development is seen as a positive step for StimCell, potentially leading to increased investor interest and support for its innovative eBalance® technology.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.